ABOUT 55,000 new prostate cancer cases are recorded every year in the UK. Bladder cancer is less common, with around 10,500 ...

In fact, prostate cancer is the second-leading cause of cancer death for men in America and the most common male cancer in ...

Men who avoided prostate cancer screening appointments were significantly more likely to die from the disease, according to ...

In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...

Feb. 3, 2025 — The incidence of advanced ... Dec. 16, 2024 — Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat.

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor pathway inhibitor.

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime.

Bachelor Nation’s Katie Thurston shared a heartbreaking update on her cancer journey after spots were found on her liver, which could put her at a stage 4 diagnosis.

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, leading to earlier diagnosis and more successful treatment. Prostate cancer ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...

Third, the study consistently showed pairwise ... resistant prostate cancer patients and in patients with early-stage prostate cancer who initially respond to androgen-receptor targeted therapies.